Dose enhancement by gold, iron oxide, bismuth oxide, and platinum nanoparticles in radiotherapy: a comprehensive meta-analysis
Abstract
This first global comprehensive meta-analysis of 64 studies compares four metal (gold (Au), iron oxide (IO), bismuth oxide (BO), platinum (Pt)) nanoparticles (NPs) as cancer radiosensitizers. Following PRISMA guidelines, we searched PubMed/Medline, Scopus, Web of Science, and Cochrane Library through November 2025 for studies on four metal NPS as cancer radiosensitizers. Meta-analysis calculated pooled dose enhancement factor (DEF) with comprehensive publication bias assessment (Egger’s, Begg’s, Trim-and-Fill, Fail-Safe N) and sensitivity analyses. Subgroup analyses examined nanoparticle size (≤ 10 nm, 10–30 nm, > 30 nm), radiation energy (≤ 100 keV, 100–250 keV, > 250 keV), and cancer cell line effects. Meta-regression evaluated size as a continuous predictor. Analysis of 95 independent data comparing four NPs revealed BO as most efficacious (0.575; 95% CI: 0.352–0.798; p = 0.001), followed by Au (0.395; 95% CI: 0.317–0.474; p = 0.001) and IO (0.293; 95% CI: 0.153–0.433; p = 0.001). Pt showed highest point estimate (0.780; 95% CI: 0.306–1.255; p = 0.001) but critically fragile evidence (Fail-Safe N = 2). Smaller NPs (≤ 10 nm, 0.500; 95% CI: 0.300–0.700) demonstrated 60% greater efficacy than 10–30 nm particles (0.312; 95% CI: 0.180–0.430). Orthovoltage radiation (≤ 100 keV0.710; 95% CI: 0.410–1.150) produced 2-fold greater enhancement than megavoltage (> 250 keV, 0.350; 95% CI: 0.240–0.460). Sensitivity analysis confirmed no influential outliers, with bismuth showing…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.